Androgen supplementation and risk for prostate cancer

A new study from a research team in Seattle investigaresthe real risks associated with androgen supplementation and subequent diagnosis of prostate cancer (or other prostate disorders).

The authors conclude that abnormally high physiologic levels of serum dihydrotestosterone (DHT), associated with decreased levels of serum testosterone, do not significantly alter intraprostatic levels of DHT, testosterone, or prostate epithelial cell androgen-regulated gene expression in healthy men.

Now it is certainly true that this study shows that, changes in circulating androgen concentrations are not necessarily mimicked within the prostate microenvironment.